drugset

Drugs / Fluzone High-Dose Quadrivalent vaccine

Follow last change Jun 2022 re-read 2 minutes ago

Fluzone High-Dose Quadrivalent vaccine

also known as Fluzone High-Dose Quadrivalent

Investigated by: Sanofi Pasteur, a Sanofi Company

Trials 1 · a red edge is where a trial was stopped

today NCT04551677 · Ph 4

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT04551677	Sep → Dec 2020	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2022-06-22	Sanofi	Media Update: Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older sanofi.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Fluzone High-Dose Quadrivalent vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04551677 ↗
Known as	Fluzone High-Dose Quadrivalent	“Fluzone High-Dose Quadrivalent” NCT04551677 ↗
Modality	Vaccine	“Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation” NCT04551677 ↗
Route	Intramuscular	“Route of administration: IM” NCT04551677 ↗